|
Clostridium difficile causes antibiotic-associated diarrhea
and colitis in animals and humans and is one of the most common
nosocomial infections seen in hospitalized patients. An estimated
10-12 million adults are infected with this organism each year in
the USA. Enzyme immuno-assays (EIA) are commonly used for diagnosis
of C. difficile-associated diarrhea (CDAD). However, these
EIA assays for toxin A and toxin B only have approximately 70% -
80% sensitivity (Peterson et al., 2007 Clin Infec Dis 45:1152-60).
Accurate identification of pathogenic C. difficile in a timely
fashion has great therapeutic, prognostic and economic significance.
The IsoAmp C.diff Detection Kit is a nucleic acid test (NAT) that
uses a target amplification method called Helicase-Dependent
Amplification (HDA). Two sequence-specific primers amplify a
conserved region of toxin A gene as well as an internal control
(IC) plasmid with scrambled sequence. The reaction takes only one
hour at 65°C and the only equipment required is a waterbath
or a heatblock.
Two labeled probes are used in the reaction to simultaneously detect
the C. difficile target (FI probe) and IC sequence (DIG probe)
and the resulting complexes are detected by the Type
II BESt cassette (a disposable device designed for rapid,
instrument-free and cross-contamination-proof detection of amplicons.)
The results are readable on the BESt cassette's strip after
5-10 minutes.
A visible T (test) line indicates positive test result, and a visible
C (control) line alone indicates negative result (see Figure 1).
If no line is shown, the assay is invalid and it can be caused by
inhibition. In this case the assay needs to be repeated with additional
dilution of the original sample.
 |
Figure 1. Typical Test Results on BESt Cassette.
(+) Positive for C. difficile
(-) Negative for C. difficile
|
|